Compare MMSI & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMSI | RLAY |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.1B |
| IPO Year | 1996 | 2020 |
| Metric | MMSI | RLAY |
|---|---|---|
| Price | $89.48 | $16.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $101.64 | $27.58 |
| AVG Volume (30 Days) | 532.4K | ★ 3.1M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.93 | ★ 31.78 |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $1,515,906,000.00 | $15,355,000.00 |
| Revenue This Year | $7.95 | N/A |
| Revenue Next Year | $6.07 | $60.51 |
| P/E Ratio | $67.47 | ★ N/A |
| Revenue Growth | 11.75 | ★ 53.44 |
| 52 Week Low | $59.74 | $5.95 |
| 52 Week High | $94.75 | $21.27 |
| Indicator | MMSI | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 36.57 |
| Support Level | $89.13 | $11.68 |
| Resistance Level | $92.22 | $17.40 |
| Average True Range (ATR) | 2.11 | 0.88 |
| MACD | 0.37 | -0.14 |
| Stochastic Oscillator | 83.79 | 0.83 |
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.